Assessment of cardiovascular outcome in SGLT2- Inhibitors pre-treated diabetic patients with Acute Myocardial Infarction undergoing primary percutaneous coronary intervention (PPCI)

Coronary artery disease progression has been found to be closely correlated with multiple chronic diseases as diabetes mellitus; diabetic patients and Acute Myocardial Infarction (AMI) face a greater risk of cardiovascular death, heart failure and major adverse cardiovascular events (MACE). Sodium-glucose cotransporter 2 inhibitors (SGLT2-I), a class of oral antidiabetic medications (OAD), are known to control the glycemic status in patients with type 2 diabetes mellitus (T2DM). Moreover, it was demonstrated though multiple randomized clinical trials that SGLT2-I significantly improve cardiovascular and renal outcomes in diabetic patients, with similar benefits observed in the non-diabetic patients diagnosed with heart failure (HF).The primary aim of this article is to serve as an assessment of the cardiovascular outcomes in diabetic patients who were pre-treated with SGLT2 inhibitors and subsequently underwent primary percutaneous coronary intervention (PPCI) for acute myocardial infarction. Furthermore, the article reviewed the findings of multiple studies and research efforts concerning cardiovascular events, including mortality rates and MACE, as well as the role of SGLT2-I in enhancing outcomes for patients presented with ST-elevation myocardial infarction (STEMI).In conclusion, compared to conventional treatment approaches; the use of SGLT2-I following myocardial infarction was related with lower rates of all causes of mortality and a reduced incidence of initial hospitalization due to heart failure